KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Retained Earnings (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Retained Earnings data on record, last reported at -$4.6 billion in Q3 2025.

  • For Q3 2025, Retained Earnings fell 6.21% year-over-year to -$4.6 billion; the TTM value through Sep 2025 reached -$4.6 billion, down 6.21%, while the annual FY2024 figure was -$218000.0, 100.0% up from the prior year.
  • Retained Earnings reached -$4.6 billion in Q3 2025 per SRPT's latest filing, down from -$51000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $34000.0 in Q1 2025 and bottomed at -$4.6 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$2.1 billion, with a median of -$3.0 billion recorded in 2021.
  • Peak YoY movement for Retained Earnings: plummeted 177162800.0% in 2022, then skyrocketed 104.92% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$3.2 billion in 2021, then surged by 99.95% to -$1.7 million in 2022, then tumbled by 267100.3% to -$4.4 billion in 2023, then soared by 100.0% to -$218000.0 in 2024, then crashed by 2129045.41% to -$4.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$4.6 billion in Q3 2025, -$51000.0 in Q2 2025, and $34000.0 in Q1 2025.